MicroRNA Market Size, Share, Opportunities, And Trends By Type (Products, Services), By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others), By End-Use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Other end-users), And By Geography - Forecasts From 2025 To 2030

MicroRNA Market Size:

MicroRNA Market, at a 13.25% CAGR, is anticipated to reach USD 3.394 billion in 2030 from USD 1.822 billion in 2025.

MicroRNA Market Key Highlights:

• Increasing clinical trials are exploring microRNA roles in complex diseases and diagnostics.
• Rising cancer prevalence is driving demand for microRNA-based personalized therapies.
• Biotech companies are launching innovative microRNA tools for research and treatment use.
• Researchers are expanding microRNA applications into agriculture, veterinary, and environmental monitoring.

MicroRNA Market Trends:

Small non-coding RNA molecules known as microRNAs (miRNAs) play a critical function in the control of gene expression in a range of organisms. It is normally made up of 21 to 25 nucleotides and is a single-stranded RNA molecule. The increasing number of clinical trials for various diseases focusing on microRNA along with the rising cases of chronic illnesses such as cancer is a major growth driver in the microRNA market. Moreover, the increasing shift towards personalized medicine coupled with technological developments and launches by the market players are further contemplated to augment the microRNA market growth.

MicroRNA Market Growth Drivers:

• Increasing Clinical Trials of MicroRNA

The molecular and cellular roles of microRNA have been identified since their discovery. The first proof of microRNAs' involvement in human disease was published in 2002 and after that numerous studies have been conducted on the relevance of microRNA in humans as well as other organisms thereby boosting the microRNA market. For instance, a recent study titled microRNAs in the Diagnosis of atherosclerotic plaque instability was started in September 2022 by Moscow State Medical University and it is estimated to be complete by August 2024. Finding biomarkers of unstable atherosclerosis in the brachiocephalic arteries is the goal of the research.

• Rising Prevalence of Cancer

The demand for efficient diagnostic and therapeutic technologies is being driven by the increasing incidence of cancer. MicroRNAs offer chances for better illness management and individualized treatments due to their participation in disease processes and potential as biomarkers or therapeutic targets. Therefore, the rising cancer cases are a major growth factor in the microRNA market. For instance, nearly 10 million deaths, or one in six deaths, were caused by cancer in 2020, making it the top cause of mortality worldwide as per the WHO data. Moreover, 400 000 kids are diagnosed with cancer in children every year according to the WHO report.

• Growing Focus on Personalized Medicine

The idea of personalized medicine, which tries to customize medical interventions for specific patients, has drawn a lot of interest. Because of their capacity to reflect both disease states and individual differences, microRNAs are potential targets for personalized treatment thereby propelling the microRNA market. The development of individualized treatment plans is aided by the capacity to examine miRNA expression profiles and create miRNA-based therapeutics. According to the American Cancer Society, in cases where a patient's chance of developing a particular cancer is higher, precision medicine may be applied. For instance, a patient might learn that cancer runs in their family, for instance, or a doctor might see a pattern of cancer in the patient's family. 

MicroRNA Market Opportunities:

The growth factors mentioned above provide an immense expansion opportunity for the microRNA market. Moreover, other factors are also offering entrance opportunities into the microRNA market. For example, microRNAs are being researched for possible applications. These include disciplines like veterinary medicine, agriculture, and environmental monitoring. Research, product development, and commercialization potential are expanded as a result of studying the function of microRNAs in various sectors.  Additionally, the funding and investments received by the companies involved in the microRNA further extend the growth opportunity thereby propelling the microRNA market. For instance, InteRNA Technologies received a total of € 18.5 million in a series B financing round held in September 2021. This money was utilized to advance the clinical assessment of the microRNA lead candidate INT 0-1B3 in patients with solid tumors that were progressed.

MicroRNA Market Restraints:

There are a few factors that are expected to limit the microRNA market. The creation of efficient diagnostic and therapeutic approaches may be hampered by a lack of a thorough understanding of miRNA biology. It is difficult to translate microRNA research into therapeutically useful uses. Rigorous clinical trials and extensive research are needed to validate the diagnostic or therapeutic value of miRNAs. It takes time, money, and proof of clinical utility to complete complex processes including clinical validation, regulatory approval, and incorporation into standard clinical practice. Moreover, efficient delivery of microRNA-based therapies to target tissues or cells is a major challenge because miRNAs are often fragile and can be swiftly destroyed in vivo.

MicroRNA Market Segmentation Analysis:

• North America is Projected to Grow Significantly

The North American region is estimated to hold a significant share of the microRNA market. Various factors attributed to such a share are favorable regulatory policies, the growing burden of chronic diseases such as cancer, and chronic kidney disease, and increasing scientific research studies. For instance, CDC estimated that 35.5 million US adults which equates to 14% of the population, were having CKD in 2022. According to the United States Renal Data System (USRDS), there were more than 750,000 people in the US who had ESRD in 2019. Additionally, the presence of major market leaders such as Thermo Fisher Scientific and BioGenex further accelerates the microRNA market in the region.

List of Top MicroRNA Companies:

• Horizon Discovery Ltd is a biotechnology business with its headquarters in the UK,  It focuses on the use of gene editing and gene modulation technologies to hasten the discovery, development, and production of novel medications, treatments, and cell-based research tools. Horizon Discovery provides CRISPR-Cas9-based gene editing tools such as guide RNA libraries, knockout cell lines, and specialized cell line engineering services.
• BioGenex specializes in automated systems and molecular pathology solutions for cancer research and cancer diagnostics. Chromogenic ISH (CISH) and fluorescence ISH (FISH) tests, which enable the identification and localization of certain nucleic acid targets inside tissue samples, are two of the wide variety of ISH solutions offered by BioGenex.
• QIAGEN is one of the leading global medical companies with a focus on sample and assay technologies for molecular diagnostics, applied testing, scholarly research, and pharmaceutical studies. QIAGEN creates and sells a variety of diagnostic platforms and assays for the diagnosis of genetic abnormalities, oncology-related mutations, infectious diseases, and other therapeutic applications.

MicroRNA Market Scope:

Report Metric	Details
MicroRNA Market Size in 2025	USD 1.822 billion
MicroRNA Market Size in 2030	USD 3.394 billion
Growth Rate	CAGR of 13.25%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Type Application End-User Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the MicroRNA Market	Thermo Fisher Scientific, Inc. Horizon Discovery Ltd. QIAGEN BioGenex GeneCopoeia, Inc.
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Type
  • Products
  • Services
• By Application
  • Cancer
  • Infectious Diseases
  • Immunological Disorder
  • Cardiovascular Disease
  • Neurological Disease
  • Others
• By End-Use
  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Other end-users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

Our Best-Performing Industry Reports:

• RNA Analysis Market
• DNA Synthesizer Market
• DNA Digital Storage Market

---

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. MICRORNA MARKET, BY TYPE

5.1. Introduction

5.2. Products

5.3. Services

6. MICRORNA MARKET, BY APPLICATION

6.1. Introduction

6.2. Cancer

6.3. Infectious Diseases

6.4. Immunological Disorder

6.5. Cardiovascular Disease

6.6. Neurological Disease

6.7. Others

7. MICRORNA MARKET, BY END-USE

7.1. Introduction

7.2. Biotechnology & Pharmaceutical Companies

7.3. Academic & Government Research Institutes

7.4. Other end-users

8. MICRORNA MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Thermo Fisher Scientific, Inc.

10.2. Horizon Discovery Ltd.

10.3. QIAGEN

10.4. BioGenex

10.5. GeneCopoeia, Inc.

10.6. NanoString

10.7. Quantabio

10.8. SeqMatic LLC

10.9. OriGene Technologies, Inc.

10.10. Illumina, Inc.

Thermo Fisher Scientific, Inc.

Horizon Discovery Ltd.

QIAGEN

BioGenex

GeneCopoeia, Inc.

NanoString

Quantabio

SeqMatic LLC

OriGene Technologies, Inc.

Illumina, Inc.